Head-To-Head Analysis: Can Fite Biopharma (CANF) & Osiris Therapeutics (OSIR)
Can Fite Biopharma (NASDAQ: CANF) and Osiris Therapeutics (NASDAQ:OSIR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.
This is a breakdown of recent ratings and target prices for Can Fite Biopharma and Osiris Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Can Fite Biopharma||0||0||2||0||3.00|
Can Fite Biopharma presently has a consensus price target of $6.50, indicating a potential upside of 293.94%. Given Can Fite Biopharma’s higher probable upside, equities analysts plainly believe Can Fite Biopharma is more favorable than Osiris Therapeutics.
Valuation & Earnings
This table compares Can Fite Biopharma and Osiris Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Can Fite Biopharma||$215,366.00||133.02||-$9.07 million||N/A||N/A|
|Osiris Therapeutics||$86.60 million||1.81||$4.41 million||N/A||N/A|
Osiris Therapeutics has higher revenue and earnings than Can Fite Biopharma.
This table compares Can Fite Biopharma and Osiris Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Can Fite Biopharma||N/A||N/A||N/A|
Insider and Institutional Ownership
19.9% of Osiris Therapeutics shares are held by institutional investors. 44.6% of Osiris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Can Fite Biopharma beats Osiris Therapeutics on 6 of the 10 factors compared between the two stocks.
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.
Osiris Therapeutics Company Profile
Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.
Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.